Hancock Whitney Corp Halozyme Therapeutics, Inc. Transaction History

Hancock Whitney Corp

$5.37 Billion
Q3 2025

A detailed history of Hancock Whitney Corp transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Hancock Whitney Corp holds 246,221 shares of HALO stock, worth $17.2 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares

246,221

Previous 235,895 4.38%

Holding current value

$17.2 Million

Previous $12.3 Million 47.15%

% of portfolio

0.34%

Previous 0.24%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 17, 2025	BUY	$52.92 - $78.28 $546,451 - $808,319	10,326 Added 4.38%	246,221 $18.1 Million
Q2 2025 Aug 14, 2025	BUY	$47.91 - $70.14 $1.54 Million - $2.25 Million	32,077 Added 15.74%	235,895 $12.3 Million
Q1 2025 May 15, 2025	BUY	$47.74 - $65.16 $3.96 Million - $5.41 Million	83,007 Added 68.71%	203,818 $13 Million
Q4 2024 Feb 14, 2025	BUY	$42.57 - $61.09 $4.43 Million - $6.35 Million	104,015 Added 619.28%	120,811 $5.78 Million
Q3 2024 Nov 13, 2024	BUY	$51.3 - $64.42 $4,104 - $5,153	80 Added 0.48%	16,796 $960,000
Q2 2024 Aug 13, 2024	BUY	$37.81 - $52.4 $426,723 - $591,386	11,286 Added 207.85%	16,716 $875,000
Q1 2024 May 16, 2024	SELL	$33.68 - $41.95 $14,785 - $18,416	-439 Reduced 7.48%	5,430 $220,000
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $266 - $336	-8 Reduced 0.14%	5,869 $216,000
Q3 2023 Nov 13, 2023	SELL	$36.46 - $44.03 $7,547 - $9,114	-207 Reduced 3.4%	5,877 $224,000
Q2 2023 Nov 13, 2023	SELL	$30.28 - $38.74 $71,006 - $90,845	-2,345 Reduced 27.82%	6,084 $219,000
Q2 2023 Aug 10, 2023	SELL	$30.28 - $38.74 $71,006 - $90,845	-2,345 Reduced 27.82%	6,084 $219,000
Q1 2023 Nov 13, 2023	SELL	$32.86 - $55.7 $37,723 - $63,943	-1,148 Reduced 11.99%	8,429 $321,000
Q1 2023 May 16, 2023	SELL	$32.86 - $55.7 $37,723 - $63,943	-1,148 Reduced 11.99%	8,429 $322,000
Q4 2022 Nov 13, 2023	BUY	$40.06 - $59.44 $139,929 - $207,623	3,493 Added 57.41%	9,577 $544,000
Q4 2022 Feb 03, 2023	SELL	$40.06 - $59.44 $801 - $1,188	-20 Reduced 0.21%	9,577 $545,000
Q3 2022 Oct 26, 2022	BUY	$38.53 - $51.78 $14,872 - $19,987	386 Added 4.19%	9,597 $379,000
Q2 2022 Aug 08, 2022	SELL	$37.35 - $48.3 $25,024 - $32,360	-670 Reduced 6.78%	9,211 $405,000
Q1 2022 May 12, 2022	BUY	$31.97 - $41.06 $4,092 - $5,255	128 Added 1.31%	9,881 $394,000
Q4 2021 Jan 25, 2022	SELL	$31.82 - $40.75 $2,131 - $2,730	-67 Reduced 0.68%	9,753 $392,000
Q3 2021 Nov 04, 2021	SELL	$38.47 - $46.42 $11,541 - $13,926	-300 Reduced 2.96%	9,820 $399,000
Q2 2021 Aug 09, 2021	SELL	$38.84 - $51.31 $566,209 - $747,997	-14,578 Reduced 59.03%	10,120 $460,000
Q1 2021 May 14, 2021	SELL	$39.51 - $51.45 $15,566 - $20,271	-394 Reduced 1.57%	24,698 $1.03 Million
Q4 2020 Feb 09, 2021	BUY	$25.81 - $43.62 $825 - $1,395	32 Added 0.13%	25,092 $1.07 Million
Q3 2020 Nov 05, 2020	SELL	$25.74 - $29.63 $978 - $1,125	-38 Reduced 0.15%	25,060 $659,000
Q2 2020 Jul 30, 2020	SELL	$16.25 - $26.81 $149,110 - $246,008	-9,176 Reduced 26.77%	25,098 $673,000
Q1 2020 May 08, 2020	BUY	$13.9 - $21.83 $134,093 - $210,594	9,647 Added 39.17%	34,274 $617,000
Q4 2019 Feb 06, 2020	SELL	$14.93 - $19.53 $165,588 - $216,607	-11,091 Reduced 31.05%	24,627 $437,000
Q3 2019 Oct 29, 2019	SELL	$15.2 - $17.69 $147,759 - $171,964	-9,721 Reduced 21.39%	35,718 $554,000
Q2 2019 Aug 29, 2019	BUY	$14.75 - $17.26 $76,390 - $89,389	5,179 Added 12.86%	45,439 $781,000
Q1 2019 May 13, 2019	BUY	$13.94 - $17.58 $120,302 - $151,715	8,630 Added 27.28%	40,260 $648,000
Q4 2018 Feb 15, 2019	SELL	$13.33 - $18.66 $193,085 - $270,290	-14,485 Reduced 31.41%	31,630 $463,000
Q3 2018 Nov 14, 2018	BUY	$16.68 - $18.41 $67,587 - $74,597	4,052 Added 9.63%	46,115 $838,000
Q2 2018 Aug 14, 2018	BUY	$16.87 - $20.3 $709,602 - $853,878	42,063 New	42,063 $710,000

Others Institutions Holding HALO

# of Institutions

666

Shares Held

128M

Call Options Held

626K

Put Options Held

455K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $9.75B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hancock Whitney Corp, based on Form 13F filings with the SEC.

News

Stay updated on Hancock Whitney Corp with notifications on news.

Account

Hancock Whitney Corp Halozyme Therapeutics, Inc. Transaction History